Oncological outcomes of whole-gland cryoablation in patients with prostate cancer and high risk of lymph node invasion.

IF 0.7 Q4 UROLOGY & NEPHROLOGY
Urology Annals Pub Date : 2023-01-01 Epub Date: 2022-11-08 DOI:10.4103/ua.ua_171_21
Oscar Selvaggio, Ugo Giovanni Falagario, Marco Finati, Salvatore Mariano Bruno, Marco Recchia, Paola Milillo, Francesca Sanguedolce, Giovanni Silecchia, Luca Macarini, Luigi Cormio, Giuseppe Carrieri
{"title":"Oncological outcomes of whole-gland cryoablation in patients with prostate cancer and high risk of lymph node invasion.","authors":"Oscar Selvaggio,&nbsp;Ugo Giovanni Falagario,&nbsp;Marco Finati,&nbsp;Salvatore Mariano Bruno,&nbsp;Marco Recchia,&nbsp;Paola Milillo,&nbsp;Francesca Sanguedolce,&nbsp;Giovanni Silecchia,&nbsp;Luca Macarini,&nbsp;Luigi Cormio,&nbsp;Giuseppe Carrieri","doi":"10.4103/ua.ua_171_21","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Prostate cryoablation has been proposed as an alternative to radical prostatectomy for men with localized prostate cancer (PCa); however, it is limited by the lack of data regarding oncological outcomes and the impossibility of performing a lymph node dissection. The aim of this study was to assess if whole-gland cryoablation is oncologically safe, especially for patients in whom pelvic lymph node dissection would be necessary.</p><p><strong>Materials and methods: </strong>After institutional review board approval, we identified 102 patients who underwent whole-gland prostate cryoablation between 2013 and April 2019. Lymph node invasion (LNI) probability was computed using Briganti nomogram, and a 5% cutoff probability was used to stratify the population in two groups. Biochemical recurrence after procedure was assessed using Phoenix criteria. Multiparametric magnetic resonance imaging, (CT), and bone scan or choline positron-emission tomography/CT were performed for the detection of distant metastases.</p><p><strong>Results: </strong>Seventeen (17%) patients were treated for a low-risk PCa, 48 (47%) patients were at intermediate-risk PCa, and 37 (36%) patients were at high-risk PCa. Patients with a probability of LNI >5% (<i>n</i> = 46) exhibited higher prostate-specific antigen (PSA), PSA density, ISUP Grade Group, CT stage, and european association of urology (EAU) risk. Recurrence-free survival rates at 3 years' follow-up were 93%, 82%, and 72%, respectively for low-, intermediate-, and high-risk patients. At a median follow-up of 37 months (17-62), additional treatment and metastasis-free survival were 84% and 97%, respectively. No differences in oncological outcomes were found in patients with a probability of LNI above and below 5%.</p><p><strong>Conclusions: </strong>Prostate whole-gland cryoablation can be considered a safe procedure with acceptable outcomes in low- and intermediate-risk patients. A high preoperative risk of nodal involvement could not be considered an exclusion criterion to perform cryoablation. Further studies are required.</p>","PeriodicalId":23633,"journal":{"name":"Urology Annals","volume":"15 1","pages":"48-53"},"PeriodicalIF":0.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/93/UA-15-48.PMC10062521.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Annals","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ua.ua_171_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/11/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Prostate cryoablation has been proposed as an alternative to radical prostatectomy for men with localized prostate cancer (PCa); however, it is limited by the lack of data regarding oncological outcomes and the impossibility of performing a lymph node dissection. The aim of this study was to assess if whole-gland cryoablation is oncologically safe, especially for patients in whom pelvic lymph node dissection would be necessary.

Materials and methods: After institutional review board approval, we identified 102 patients who underwent whole-gland prostate cryoablation between 2013 and April 2019. Lymph node invasion (LNI) probability was computed using Briganti nomogram, and a 5% cutoff probability was used to stratify the population in two groups. Biochemical recurrence after procedure was assessed using Phoenix criteria. Multiparametric magnetic resonance imaging, (CT), and bone scan or choline positron-emission tomography/CT were performed for the detection of distant metastases.

Results: Seventeen (17%) patients were treated for a low-risk PCa, 48 (47%) patients were at intermediate-risk PCa, and 37 (36%) patients were at high-risk PCa. Patients with a probability of LNI >5% (n = 46) exhibited higher prostate-specific antigen (PSA), PSA density, ISUP Grade Group, CT stage, and european association of urology (EAU) risk. Recurrence-free survival rates at 3 years' follow-up were 93%, 82%, and 72%, respectively for low-, intermediate-, and high-risk patients. At a median follow-up of 37 months (17-62), additional treatment and metastasis-free survival were 84% and 97%, respectively. No differences in oncological outcomes were found in patients with a probability of LNI above and below 5%.

Conclusions: Prostate whole-gland cryoablation can be considered a safe procedure with acceptable outcomes in low- and intermediate-risk patients. A high preoperative risk of nodal involvement could not be considered an exclusion criterion to perform cryoablation. Further studies are required.

Abstract Image

Abstract Image

全陆地冷冻消融治疗前列腺癌症和高淋巴结侵袭风险患者的肿瘤结果。
目的:前列腺冷冻消融术已被提议作为局部前列腺癌症(PCa)男性根治性前列腺切除术的替代方案;然而,由于缺乏肿瘤学结果的数据以及不可能进行淋巴结清扫,这一方法受到了限制。本研究的目的是评估全腺体冷冻消融在肿瘤学上是否安全,尤其是对于需要进行盆腔淋巴结清扫的患者。材料和方法:在机构审查委员会批准后,我们确定了在2013年至2019年4月期间接受全腺前列腺冷冻消融的102名患者。使用Briganti列线图计算淋巴结侵袭(LNI)概率,并使用5%的截断概率将人群分为两组。使用Phoenix标准评估手术后的生化复发。多参数磁共振成像(CT)和骨扫描或胆碱正电子发射断层扫描/CT用于检测远处转移。结果:17名(17%)患者接受了低风险前列腺癌治疗,48名(47%)患者处于中风险前列腺癌,37名(36%)患者处于高风险前列腺癌。LNI概率>5%的患者(n=46)表现出较高的前列腺特异性抗原(PSA)、PSA密度、ISUP分级组、CT分期和欧洲泌尿外科协会(EAU)风险。低、中、高危患者3年随访无复发生存率分别为93%、82%和72%。在中位随访37个月(17-62)时,额外治疗和无转移生存率分别为84%和97%。在LNI概率高于和低于5%的患者中,未发现肿瘤学结果的差异。结论:前列腺全腺冷冻消融是一种安全的手术,在中低风险患者中具有可接受的结果。术前淋巴结受累的高风险不能被视为进行冷冻消融的排除标准。还需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Urology Annals
Urology Annals UROLOGY & NEPHROLOGY-
CiteScore
1.20
自引率
0.00%
发文量
59
审稿时长
31 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信